391 related articles for article (PubMed ID: 27465879)
1. Tenofovir Alafenamide.
Gibson AK; Shah BM; Nambiar PH; Schafer JJ
Ann Pharmacother; 2016 Nov; 50(11):942-952. PubMed ID: 27465879
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of the regimens containing tenofovir alafenamide versus tenofovir disoproxil fumarate in fixed-dose single-tablet regimens for initial treatment of HIV-1 infection: A meta-analysis of randomized controlled trials.
Tao X; Lu Y; Zhou Y; Zhang L; Chen Y
Int J Infect Dis; 2020 Apr; 93():108-117. PubMed ID: 31988012
[TBL] [Abstract][Full Text] [Related]
3. Superior Efficacy and Improved Renal and Bone Safety After Switching from a Tenofovir Disoproxil Fumarate- to a Tenofovir Alafenamide-Based Regimen Through 96 Weeks of Treatment.
DeJesus E; Haas B; Segal-Maurer S; Ramgopal MN; Mills A; Margot N; Liu YP; Makadzange T; McCallister S
AIDS Res Hum Retroviruses; 2018 Apr; 34(4):337-342. PubMed ID: 29368537
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study.
Mills A; Crofoot G; McDonald C; Shalit P; Flamm JA; Gathe J; Scribner A; Shamblaw D; Saag M; Cao H; Martin H; Das M; Thomas A; Liu HC; Yan M; Callebaut C; Custodio J; Cheng A; McCallister S
J Acquir Immune Defic Syndr; 2015 Aug; 69(4):439-45. PubMed ID: 25867913
[TBL] [Abstract][Full Text] [Related]
5. Tenofovir alafenamide, emtricitabine, elvitegravir, and cobicistat combination therapy for the treatment of HIV.
Imaz A; Podzamczer D
Expert Rev Anti Infect Ther; 2017 Mar; 15(3):195-209. PubMed ID: 28117606
[TBL] [Abstract][Full Text] [Related]
6. Elvitegravir, cobicistat, emtricitabine and tenofovir alafenamide for the treatment of HIV in adults.
Bonora S; Calcagno A; Trentalange A; Di Perri G
Expert Opin Pharmacother; 2016; 17(3):409-19. PubMed ID: 26642079
[TBL] [Abstract][Full Text] [Related]
7. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
[TBL] [Abstract][Full Text] [Related]
8. Brief Report: Randomized, Double-Blind Comparison of Tenofovir Alafenamide (TAF) vs Tenofovir Disoproxil Fumarate (TDF), Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine (E/C/F) for Initial HIV-1 Treatment: Week 144 Results.
Arribas JR; Thompson M; Sax PE; Haas B; McDonald C; Wohl DA; DeJesus E; Clarke AE; Guo S; Wang H; Callebaut C; Plummer A; Cheng A; Das M; McCallister S
J Acquir Immune Defic Syndr; 2017 Jun; 75(2):211-218. PubMed ID: 28282300
[TBL] [Abstract][Full Text] [Related]
9. Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study.
Sax PE; Zolopa A; Brar I; Elion R; Ortiz R; Post F; Wang H; Callebaut C; Martin H; Fordyce MW; McCallister S
J Acquir Immune Defic Syndr; 2014 Sep; 67(1):52-8. PubMed ID: 24872136
[TBL] [Abstract][Full Text] [Related]
10. A Review of the Efficacy and Safety of Genvoya® (Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide) in the Management of HIV-1 Infection.
Angione SA; Cherian SM; Özdener AE
J Pharm Pract; 2018 Apr; 31(2):216-221. PubMed ID: 28558493
[TBL] [Abstract][Full Text] [Related]
11. Tenofovir alafenamide (TAF) as the successor of tenofovir disoproxil fumarate (TDF).
De Clercq E
Biochem Pharmacol; 2016 Nov; 119():1-7. PubMed ID: 27133890
[TBL] [Abstract][Full Text] [Related]
12. Rilpivirine, emtricitabine and tenofovir alafenamide: single-tablet combination for the treatment of HIV-1 infection in selected patients.
Ogbuagu O
Expert Rev Anti Infect Ther; 2016 Dec; 14(12):1113-1126. PubMed ID: 27797606
[TBL] [Abstract][Full Text] [Related]
13. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
[TBL] [Abstract][Full Text] [Related]
14. Seminal Tenofovir Concentrations, Viral Suppression, and Semen Quality With Tenofovir Alafenamide, Compared With Tenofovir Disoproxil Fumarate (Spanish HIV/AIDS Research Network, PreEC/RIS 40).
Imaz A; Niubó J; Cottrell ML; Perez E; Kashuba ADM; Tiraboschi JM; Morenilla S; Garcia B; Podzamczer D
Clin Infect Dis; 2019 Sep; 69(8):1403-1409. PubMed ID: 30561517
[TBL] [Abstract][Full Text] [Related]
15. [Tenofovir alafenamide fumarate - a new generation of tenofovir].
Snopková S; Havlíčková K; Husa P
Klin Mikrobiol Infekc Lek; 2016 Sep; 22(3):111-117. PubMed ID: 27907972
[TBL] [Abstract][Full Text] [Related]
16. Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.
Gotham D; Hill A; Pozniak AL
Curr Opin HIV AIDS; 2017 Jul; 12(4):324-333. PubMed ID: 28403027
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.
Venter WDF; Moorhouse M; Sokhela S; Fairlie L; Mashabane N; Masenya M; Serenata C; Akpomiemie G; Qavi A; Chandiwana N; Norris S; Chersich M; Clayden P; Abrams E; Arulappan N; Vos A; McCann K; Simmons B; Hill A
N Engl J Med; 2019 Aug; 381(9):803-815. PubMed ID: 31339677
[TBL] [Abstract][Full Text] [Related]
18. Brief Report: A Randomized, Double-Blind Comparison of Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate, Each Coformulated With Elvitegravir, Cobicistat, and Emtricitabine for Initial HIV-1 Treatment: Week 96 Results.
Wohl D; Oka S; Clumeck N; Clarke A; Brinson C; Stephens J; Tashima K; Arribas JR; Rashbaum B; Cheret A; Brunetta J; Mussini C; Tebas P; Sax PE; Cheng A; Zhong L; Callebaut C; Das M; Fordyce M;
J Acquir Immune Defic Syndr; 2016 May; 72(1):58-64. PubMed ID: 26829661
[TBL] [Abstract][Full Text] [Related]
19. Treatment with tenofovir alafenamide fumarate worsens the lipid profile of HIV-infected patients versus treatment with tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine.
Cid-Silva P; Fernández-Bargiela N; Margusino-Framiñán L; Balboa-Barreiro V; Mena-De-Cea Á; López-Calvo S; Vázquez-Rodríguez P; Martín-Herranz I; Míguez-Rey E; Poveda E; Castro-Iglesias Á
Basic Clin Pharmacol Toxicol; 2019 Apr; 124(4):479-490. PubMed ID: 30388308
[TBL] [Abstract][Full Text] [Related]
20. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]